ERR2208933
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.300
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- KRAS_SIGNALING_DN+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PEROXISOME+0.200
- SPERMATOGENESIS+0.200
- E2F_TARGETS+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- IL6_JAK_STAT3_SIGNALING-0.600
- TNFA_SIGNALING_VIA_NFKB-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- TGF_BETA_SIGNALING-0.500
- ANGIOGENESIS-0.400
- APOPTOSIS-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943037 | — | — | 0.911 |
| 2 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.893 |
| 3 | TCGA-S3-AA12-01A-11R-A41B-07 | — | B | 0.890 |
| 4 | R16 | — | — | 0.887 |
| 5 | TCGA-B6-A0IB-01A-11R-A034-07 | — | B | 0.881 |
| 6 | TCGA-GV-A40G-01A-11R-A23N-07 | — | — | 0.875 |
| 7 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.875 |
| 8 | ERR2278863 | — | — | 0.869 |
| 9 | R230 | — | — | 0.868 |
| 10 | TCGA-60-2716-01A-01R-0851-07 | — | cohortSQ1 | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |